Igm Biosciences Stock Price To Earnings To Growth

IGMS Stock

USD 10.43 0.97 10.25%

IGM Biosciences fundamentals help investors to digest information that contributes to IGM Biosciences' financial success or failures. It also enables traders to predict the movement of IGM Stock. The fundamental analysis module provides a way to measure IGM Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IGM Biosciences stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

IGM Biosciences Company Price To Earnings To Growth Analysis

IGM Biosciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

IGM Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for IGM Biosciences is extremely important. It helps to project a fair market value of IGM Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since IGM Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IGM Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IGM Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Capital Stock
Total Assets		-0.34	0.97	-0.79	-0.8	0.7	0.95	0.65	0.95	1.0	1.0	0.98	0.87	0.71	0.89	0.96
Total Stockholder Equity	-0.34		-0.27	0.3	-0.09	-0.46	-0.15	0.07	-0.37	-0.35	-0.35	-0.38	0.02	-0.74	-0.14	-0.13
Net Tangible Assets	0.97	-0.27		-0.85	-0.72	0.8	0.94	0.5	0.98	0.97	0.98	0.97	0.79	0.75	0.86	0.94
Net Debt	-0.79	0.3	-0.85		0.48	-0.92	-0.77	-0.25	-0.87	-0.8	-0.82	-0.75	-0.57	-0.67	-0.8	-0.68
Retained Earnings	-0.8	-0.09	-0.72	0.48		-0.25	-0.89	-0.93	-0.64	-0.78	-0.76	-0.76	-0.98	-0.2	-0.9	-0.88
Accounts Payable	0.7	-0.46	0.8	-0.92	-0.25		0.66	-0.02	0.86	0.72	0.74	0.72	0.35	0.86	0.62	0.58
Capital Surpluse	0.95	-0.15	0.94	-0.77	-0.89	0.66		0.7	0.91	0.94	0.93	0.94	0.92	0.59	0.96	0.96
Total Liab	0.65	0.07	0.5	-0.25	-0.93	-0.02	0.7		0.43	0.63	0.61	0.59	0.91	0.02	0.74	0.71
Net Invested Capital	0.95	-0.37	0.98	-0.87	-0.64	0.86	0.91	0.43		0.96	0.97	0.96	0.74	0.83	0.83	0.89
Total Current Assets	1.0	-0.35	0.97	-0.8	-0.78	0.72	0.94	0.63	0.96		1.0	0.98	0.86	0.73	0.88	0.95
Net Working Capital	1.0	-0.35	0.98	-0.82	-0.76	0.74	0.93	0.61	0.97	1.0		0.98	0.84	0.74	0.87	0.94
Common Stock	0.98	-0.38	0.97	-0.75	-0.76	0.72	0.94	0.59	0.96	0.98	0.98		0.83	0.78	0.86	0.95
Property Plant Equipment	0.87	0.02	0.79	-0.57	-0.98	0.35	0.92	0.91	0.74	0.86	0.84	0.83		0.31	0.91	0.91
Current Deferred Revenue	0.71	-0.74	0.75	-0.67	-0.2	0.86	0.59	0.02	0.83	0.73	0.74	0.78	0.31		0.46	0.57
Net Receivables	0.89	-0.14	0.86	-0.8	-0.9	0.62	0.96	0.74	0.83	0.88	0.87	0.86	0.91	0.46		0.89
Capital Stock	0.96	-0.13	0.94	-0.68	-0.88	0.58	0.96	0.71	0.89	0.95	0.94	0.95	0.91	0.57	0.89

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict IGM Biosciences

IGM Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.21

At this time, IGM Biosciences' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, IGM Biosciences has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

IGM Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IGM Biosciences' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IGM Biosciences could also be used in its relative valuation, which is a method of valuing IGM Biosciences by comparing valuation metrics of similar companies.

IGM Biosciences is currently under evaluation in price to earnings to growth category among its peers.

IGM Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of IGM Biosciences from analyzing IGM Biosciences' financial statements. These drivers represent accounts that assess IGM Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of IGM Biosciences' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	343.3M	2.7B	982.0M	706.7M	434.7M	594.6M
Enterprise Value	322.1M	2.5B	877.4M	626.6M	362.7M	537.0M

IGM Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, IGM Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to IGM Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

IGM Fundamentals

	Return On Equity	-1.32
	Return On Asset	-0.37
	Operating Margin	(124.78) %
	Current Valuation	389.6 M
	Shares Outstanding	34.08 M
	Shares Owned By Insiders	35.04 %
	Shares Owned By Institutions	63.98 %
	Number Of Shares Shorted	2.84 M
	Price To Earning	(7.72) X
	Price To Book	7.13 X
	Price To Sales	212.55 X
	Revenue	2.13 M
	Gross Profit	1.07 M
	EBITDA	(253.36 M)
	Net Income	(246.42 M)
	Cash And Equivalents	469.14 M
	Cash Per Share	10.95 X
	Total Debt	40.51 M
	Debt To Equity	0.09 %
	Current Ratio	10.79 X
	Book Value Per Share	1.33 X
	Cash Flow From Operations	(192.23 M)
	Short Ratio	11.97 X
	Earnings Per Share	(3.61) X
	Target Price	19.6
	Number Of Employees	198
	Beta	0.19
	Market Capitalization	620.21 M
	Total Asset	423.41 M
	Retained Earnings	(821.24 M)
	Working Capital	305.12 M
	Current Asset	1.23 M
	Current Liabilities	3.37 M
	Net Asset	423.41 M

About IGM Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze IGM Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IGM Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IGM Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC